Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05587972 · ClinicalTrials.gov registry record · NA

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring

A NA study of Breast Cancer and Multiple Myeloma, sponsored by Carevive Systems.

Active
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT05587972: Active NA study of Breast Cancer and Multiple Myeloma, sponsored by Carevive Systems.

NCT05587972 is a NA study of Breast Cancer and Multiple Myeloma that is active but no longer recruiting, run by Carevive Systems. The registered enrollment target is 100 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05587972, a NA study of Breast Cancer and Multiple Myeloma, is active but no longer recruiting, sponsored by Carevive Systems.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The Carevive registry collects patient characteristics, patient symptoms, and treatment experience data from patients receiving cancer treatment for breast, lung, GI or multiple myeloma. For this study, a core set of variables is collected on each patient in the Carevive platform. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic Patient Reported Outcome surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.

Primary Outcome

Project outcome measures for this project are the prevalence, frequency, and severity of symptoms in each disease group, longitudinal change in symptom experience, and time on treatment from enrollment to next treatment.

Interventions

  • OTHER survey

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-10-06
Est. Completion 2026-12-06
Phase NA
Carevive Systems

10 total trials

What the registry record for NCT05587972 still lists

NCT05587972 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).

The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which survey is the first listed.

NCT05587972 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05587972 about?

NCT05587972 is a clinical study titled "Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring". The Carevive registry collects patient characteristics, patient symptoms, and treatment experience data from patients receiving cancer treatment for breast, lung, GI or multiple myeloma. For this study, a core set of variables is collected on each patient in the Carevive platform. Patients will comp...

What is the current status of trial NCT05587972?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-10-06. Estimated completion is 2026-12-06.

What conditions does trial NCT05587972 study?

This clinical trial studies the following conditions: Breast Cancer, Multiple Myeloma, Lung Cancer, Gastrointestinal Cancer.

What interventions are being tested in trial NCT05587972?

The interventions under investigation include: survey (OTHER).

Who is sponsoring clinical trial NCT05587972?

This trial is sponsored by Carevive Systems, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05587972 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05587972's enrollment target sits among peer trials

100 565th of 1224 higher than 630 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05587972, the US trial registry maintained by the National Library of Medicine. NCT05587972 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.